Gilead Sciences' already dominant position in HIV pre-exposure prophylaxis (PrEP) could be extended if the FDA approves a new twice-yearly product later this year. The US regulator has started a ...

Revenue: US$28.8b (up 6.0% from FY 2023). Net income: US$480.0m (down 92% from FY 2023). Profit margin: 1.7% (down from 21% in FY 2023). EPS: US$0.39 (down from US$4.54 in FY 2023). Revenue ...

PALM BEACH GARDENS — Tiger Woods gave no hint as to when he will return to the PGA Tour, including if he might enter the Cognizant Classic in the Palm Beaches, saying he hasn't "thought about ...

(RTTNews) - Gilead Sciences (GILD) announced that the FDA has accepted its New Drug Application submissions for lenacapavir-the twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

According to the Hebron Fire Department, at around 4:48 p.m. firefighters and troopers were deployed to the scene of Gilead Street for reports of a two-car accident involving a rollover.

As of 1530 GMT, the Dow Jones Industrial Average was down 0.84% at 43,806.06, while the S&P 500 lost 0.55% to 6,083.83 and ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.